New naloxone nasal spray at least doubles the dose
The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products.
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.
Related News Articles
Blog
In our previous blog, we examined what the AHA’s affordability recommendations could mean for patients. Now we turn to another critical stakeholder group:…
Headline
The House Ways and Means Committee July 1 voted along party lines to advance a bill, H.R. 9504, the Tax-Exempt Hospitals Transparency Act, that would add…
Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Headline
The AHA today responded to a Centers for Medicare & Medicaid Services request for information on its Comprehensive Regulations to Uncover Suspicious…
Headline
The Department of Health and Human Services and Centers for Medicare & Medicaid Services announced members of the Healthcare Advisory Committee March 26.…
Headline
The Department of Health and Human Services March 20 released a final rule establishing a standard format for attachments to support electronic health care…